Private Equity

Quoin Pharma is making a bold bet, building a full commercial operation in Japan for its rare disease drug years before a potential launch. Is this the new model?

As institutional capital seeks refuge from market volatility, Stable Asset Management's $100M backing of Zenzic Capital signals a major bet on specialist credit.

A public company is offering a volatile mix of OpenAI, Worldcoin, and MrBeast. We deconstruct the high-risk, high-reward strategy behind its unique treasury.

The appointment of Bethany Sensenig, a veteran of PE-backed turnarounds, signals CenExel is preparing for a major push to dominate the clinical research market.

A PR firm launches a daily financial newsletter for the lower middle market, betting that speed and focus can win over dealmakers in a crowded, vital field.

Verdantas' latest acquisition of New Jersey-based Yu & Associates signals a major push to dominate the Northeast's engineering and environmental market.

A new firm, Nortiva Bio, is launching with tech from MIT to turn daily pills into monthly doses, starting with a contraceptive backed by the Gates Foundation.

Dr. Glenn Parker's recent award is more than a trophy. It's a signal of a quiet revolution in healthcare—one that uses fintech to build national resilience.

With a fresh $50M, Enhanced Group is selling a future of medically-guided peak performance. But can its controversial Games and peptide platform survive regulatory scrutiny?

Verite Capital Partners appoints biodiesel pioneer Sumit Majumdar as CSO, leveraging $27B in capital to create 1M green jobs and cut global emissions.

A DoW contract for in-orbit refueling thrusts Quantum Space into the spotlight, promising to redefine space warfare and ignite the orbital logistics economy.

With a fresh $260M, Dream is building AI for nations to own. But as governments rush for digital autonomy, are we creating a new digital iron curtain?

A new study reveals Canadians will pay $94.4 billion in debt interest this year, diverting funds from healthcare, education, and future growth.

After a 20-year drought, positive Phase 3 data for oral olorofim signals a safer, potent new option against a deadly fungus, promising a major market shake-up.

With 2.25M developers and advanced hybrid cloud adoption, India isn't just joining the cloud native world; it's rewriting the rules for global innovation.

Amid a resurgent SPAC market, Wilco 63 launches a $200M hunt for a tech unicorn in AI and robotics. Can it navigate a landscape that now values execution over hype?

Netlist's new patent lawsuits over HBM and DDR5 memory could disrupt the AI supply chain, putting the tech giants' critical components in legal peril.

With a $150M war chest, E. Scott Crist's latest SPAC hunts for an industrial tech gem. But can a team with a mixed track record deliver in this new era?

Office Properties Income Trust emerges from bankruptcy with $714M less debt and new owners. Is its strategic overhaul a model for a sector in crisis?

abrdn's Asia-Pacific Income Fund (FAP) just boosted its monthly distribution by 14%. We deconstruct what this means for income investors amid market complexities.